biological source
rabbit
antibody product type
primary antibodies
clone
polyclonal
form
liquid
does not contain
preservative
species reactivity
human, rat
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
isotype
IgG
shipped in
wet ice
storage temp.
−20°C
General description
This product has been discontinued.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in Sk-BR-3 cells.
Purified rabbit polyclonal antibody. Recognizes the ~185 kDa native and denatured forms of c-ErbB2/c-Neu.
Immunogen
a synthetic peptide (LARLLDIDETEYHAD) corresponding to amino acids 866-880 from the kinase domain of human c-Neu
Application
Immunoblotting (1-5 µg/ml)
Immunofluorescence (1-5 µg/ml)
Immunoprecipitation (1-2 µg/sample)
Paraffin Sections (1-10 µg/ml, saponin pre-treatment required, see application references)
Immunofluorescence (1-5 µg/ml)
Immunoprecipitation (1-2 µg/sample)
Paraffin Sections (1-10 µg/ml, saponin pre-treatment required, see application references)
Packaging
Please refer to vial label for lot-specific concentration.
Analysis Note
Negative Control
Normal human fibroblasts
Normal human fibroblasts
Positive Control
SK-BR-3 cells
SK-BR-3 cells
Other Notes
Antibody should be titrated for optimal results in individual sample types.
Di Fiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
未找到合适的产品？
试试我们的产品选型工具.
法规信息
新产品
此项目有
M Blick et al.
Blood, 64(6), 1234-1239 (1984-12-01)
The transforming genes of retroviruses (v-onc) are derived from normal cellular genes referred to as proto-oncogenes. These cellular genes have the capacity for conversion to oncogenes (c-onc) that are capable of inducing or maintaining the transformed state when they are
J M Varley et al.
Oncogene, 1(4), 423-430 (1987-01-01)
We have examined the genomic organisation of c-myc, N-myc, L-myc, neu and N-ras in tissue from 41 breast carcinomas, lymph node metastases from 10 of these carcinomas, one fibrosarcoma, 10 cases of benign fibrocystic breast and six fibroadenomas. We have
T Yamamoto et al.
Nature, 319(6050), 230-234 (1986-01-16)
A novel v-erb-B-related gene, c-erb-B-2, which has been identified in the human genome, maps to human chromosome 17 at q21 (ref. 40), and seems to encode a polypeptide with a kinase domain that is highly homologous with, but distinct from
P P Di Fiore et al.
Science (New York, N.Y.), 237(4811), 178-182 (1987-07-10)
A wide variety of human tumors contain an amplified or overexpressed erbB-2 gene, which encodes a growth factor receptor-like protein. When erbB-2 complementary DNA was expressed in NIH/3T3 cells under the control of the SV40 promoter, the gene lacked transforming
Jaime Lindsay et al.
Clinical and translational science, 1(2), 107-115 (2008-09-01)
The ErbB2 (Her2/neu epidermal growth receptor family) oncogene is overexpressed in 30% to 40% of human breast cancers. Cyclin D1 is the regulatory subunit of the holoenzyme that phosphorylates and inactivates the retinoblastoma (pRb) tumor suppressor and is an essential
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持